Human Genome Sciences' Benlysta is expected to receive FDA approval this week for the treatment of lupus, the first lupus drug in more than 50 years. Analysts are expecting this to be a blockbuster with peak estimates ranging from $3-$5 billion annually.
This type of revenue (and more importantly profits) is transformational for HGS which is currently running in the red. Some analysts predict it will become ripe for takeovers virtually overnight post-approval. GSK is partnering with HGS on the drug and they are expected to market it aggressively in the US and expect approval in Europe in the latter half of 2011. HGS has also just added a new 150 person sales force. See Fierce Biotech and MNT.
Posted by Bruce Lehr March 8th 2011.